AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00993421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Metoprolol
Description: given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
Study NCT00993421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Metoprolol
Description: given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
Study NCT00993421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LY377604
Description: given daily, orally for 24 weeks
Study NCT04435184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Description: Crizanlizumab 5.0 mg/kg in 100 ml IV once.
Study NCT04435184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline 100 ml IV once.
Study NCT03316547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SENSE Program
Description: Specific amounts of auditory, tactile, vestibular, kinesthetic, and visual exposure conducted daily through hospitalization. This includes specifically timed and set amounts of reading/talking/singing, cycled lighting, skin-to-skin (kangaroo) care or gentle human touch, rocking, and therapeutic exercises \[passive range of motion (PROM), gentle stretching\]. The intervention plan is intended to be implemented by parents when available, and by surrogates when the parents are unable to be present in the hospital. Specific amounts and timing of interventions will be tailored to the current medical status and age of each infant.
Study NCT01179711 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Glasses prescription
Description: At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
Study NCT04800679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: receive 4 monthly IVB injections and then rescue IVB
Description: IVB group that receive 4 monthly IVB injections and then rescue IVB
Study NCT04800679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRP group
Description: PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB
Study NCT04800679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVB injections and a modified laser
Description: Combination group that receive 2 bimonthly IVB injections and a modified laser (1 session anterior to the equator) and then rescue IVB or laser
Study NCT00562523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
Study NCT02620436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Mother Shelter Model
Description: 1. Infrastructure, Supplies, Equipment: All MHs will have: latrines, lockable cupboards, doors, windows, lighting, mattresses, mosquito nets, cooking space and utensils, and a bathing site.~2. Policies, Management, Finances:. The policies, management, and financial structures will follow the same general principles, but will be site-specific to account for cultural variation.~3. Linkages with Health Facilities: Each MH will be operationally linked to the health facility and 1) ensure daily check-ins by a health facility staff; 2) ensure every pregnant woman has someone able to contact a staff if she is incapacitated; and 3) will orient women to procedures upon arrival. Clinical services will be conducted at the health facility.
Study NCT00143247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exubera® (inhaled insulin)
Description: Treatment of type 1 and type 2 diabetes with short-acting insulin
Study NCT04209114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy (RC)
Description: Surgical removal of the bladder
Study NCT04209114 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical cystectomy (RC)
Description: Surgical removal of the bladder
Study NCT04209114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin
Description: Specified dose on specified days
Study NCT01919788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (Insuman Rapid)
Study NCT01919788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Study NCT01919788 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT04117802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maple syrup
Description: Substitution of refined sugar by an equivalent quantity of maple syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with maple syrup.
Study NCT04117802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Substitution of refined sugar by an equivalent quantity of maple-flavored sucrose syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with the placebo (sucrose syrup).
Study NCT03048552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family CONNECT
Description: Linkage specialists, who are clinical social workers and embedded within the probation departments, will work with specifically caregiver-youth dyads in the Family CONNECT arm to link youth to substance use services.
Study NCT02865460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubiquinol
Description: Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
Study NCT02129478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg).
Study NCT02526082 — intervention group
Intervention type: OTHER
Intervention: Intervention
Description: Multifactorial intervention with lifestyle changes and drugs as needed
Study NCT01480973 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
Study NCT02088502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Study NCT02088502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Study NCT02088502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride
Description: All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
Study NCT01298102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)
Description: intramuscular injection of 1 dose vaccine
Study NCT01053013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RENCA macrobeads
Study NCT01073540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin suspension (Optocef, BAYO5448)
Description: Single dose of 500 mg / 10 mL
Study NCT01073540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin suspension (Keflex)
Description: Single dose of 500 mg / 20 mL
Study NCT03225768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Training
Description: Guided training is an intervention strategy designed to help individuals identify barriers in their daily life and guide them to generate their own strategies to address these barriers. This intervention strategy is different from traditional direct skill training, in which rehabilitation practitioners are responsible for identifying their patients' challenges to perform activities and teaching them task-specific problem-solving strategies. Guided training has been applied in a variety of clinical populations, including individuals with stroke and TBI, and has demonstrated significant effect on improving independence with daily activities among persons with acute stroke-related cognitive impairments enrolled in inpatient rehabilitation.
Study NCT04214483 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study.
Study NCT01823783 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Muscle biopsy
Description: Muscle biopsy
Study NCT02546440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate
Description: dose escalation from 30 mg/d to maximally 720 mg/d over 9 weeks, then continuing with the highest tolerated dose following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until either progression or unacceptable side effects occur
Study NCT00497328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylcysteine
Study NCT00497328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Bicarbonate
Study NCT03351686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.
Study NCT04509245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone
Description: During the 12-week intervention participants were asked to adhere to a real food-based low-calorie diet supported by an app-guided digital education program as well as a low-calorie recipe book and received weekly coaching calls by nutritionists
Study NCT01479595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBX258
Description: QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
Study NCT01479595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
Study NCT02255565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Dose Quillivant XR
Description: Oral suspension dose once a day increasing to a 10mg dose
Study NCT03704519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY1841788)
Description: 300 mg tablet darolutamide, once orally
Study NCT00002494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00002494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00002494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Study NCT03704519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 4 x 40 mg capsules, once orally
Study NCT02255565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Quillivant XR
Description: Oral suspension dose once a day increasing to a 20mg dose
Study NCT02255565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate Dose Quillivant XR
Description: Oral suspension dose once a day increasing to a 40mg dose
Study NCT03704519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 placebo tablets, once orally
Study NCT01720706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA Loosely wound thermal coil
Description: This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.~This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode.
Study NCT02661932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.~Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis.
Study NCT02045498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capnography feedback
Description: capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
Study NCT02550548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP infusion
Description: after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
Study NCT04127552 — intervention group
Intervention type: PROCEDURE
Intervention: Adrenalectomy
Description: Adrenalectomy accordint to 2016 ESE guidelines
Study NCT03371316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ViaShield
Description: Anti-adhesion scores using amnion patch
Study NCT02139735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: 3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally
Study NCT02139735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound associated with stretching
Description: 3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips
Study NCT02139735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
Study NCT01736449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01181232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem MR
Description: oral
Study NCT01204229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational and Cognitive Intervention for Drinkers (MCID)
Description: Integrate social anxiety/ depression and drinking intervention
Study NCT01204229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Description: Integrate drinking intervention
Study NCT02719119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monthly Endoscopic Variceal Ligation (EVL)
Description: Patients in this group will underwent endoscopic variceal ligation monthly.
Study NCT02719119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bi-weekly Endoscopic Variceal Ligation (EVL)
Description: Patients in this group will underwent endoscopic variceal ligation bi-weekly.
Study NCT02928003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung surgery
Description: Genetic analysis and questionnaires
Study NCT01181232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem IR
Description: oral
Study NCT03998059 — intervention group
Intervention type: PROCEDURE
Intervention: splenectomy
Description: These patients should fail to have sustained response to multiple first- and second-line treatments of ITP and agree to have splenectomy.Before splenectomy, these patients will be reassessed and still diagnosed with ITP.Their platelet level will be raised to a safe state before surgery, and the laparoscopic splenectomy will be performed in Tianjin People's Hospital.
Study NCT00330044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premetrexed (Alimta)
Study NCT00330044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01680692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivicaine
Description: Infusion of local anesthetic for post-operative analgesia.
Study NCT01680692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Description: Infusion of local anesthetic for post-operative analgesia.
Study NCT01680692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Femoral Nerve Catheter
Description: Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
Study NCT01680692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Femoral Nerve Catheter
Description: Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
Study NCT01680692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Tibial Nerve Catheter
Description: Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
Study NCT00300482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks
Study NCT00300482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks
Study NCT00300482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin Calcium
Description: Daily, 12 weeks, see Arm Description for dosage information
Study NCT00300482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin Calcium
Description: Daily, 12 weeks, see Arm Description for dosage information
Study NCT00300482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, 12 weeks, see Arm Description for information regarding placebo type
Study NCT01878110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMB
Study NCT03168243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Energy High Protein Tube Feed
Description: Following a 3 day baseline period all patients will receive the high energy, high protein tube feed for a period of 4 weeks (28 days).
Study NCT01389531 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rigid bronchoscopy
Description: The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
Study NCT02550548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Description: after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused
Study NCT02550548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ex-9 infusion
Description: Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
Study NCT03698747 — intervention group
Intervention type: DEVICE
Intervention: McDESPOT
Description: myelin specific MRI sequence (mcDESPOT) added to standard MRI sequence
Study NCT02515123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Motion System
Description: E-Motion Tube: A disposable oro/nasogastric feeding tube fitted with stainless steel electrodes along its length that delivers the stimulation to the esophageal mucosa.~E-motion EPG 1000: a durable, touchscreen operated, bedside control unit that generates the electric stimulation pattern and sends it via the feeding tube to the esophagus.~By applying predetermined sequences of electrical stimulation to various locations along the esophagus asynchronous esophageal motion is induced, resulting is reduction of reflux and increased GI motility, enabling safer and better feeding.
Study NCT02515123 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham E-Motion System
Description: The sham EPG will resemble the investigational EPG. The external shape, interface, lights, and switches will be exactly the same. The Sham device will emit a low intensity pulsation so that, it will not unblind the patient nor health care professional. In the event that unblinding does occur, we will take steps to mask the identity of the EPG by covering the number of the device with tape to prevent members of the clinical team becoming aware of which device is active or sham.
Study NCT01317966 — intervention group
Intervention type: DRUG
Intervention: rhIL-11
Description: Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
Study NCT03494413 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transpharyngeal Doppler sonography (TPS)
Description: Usage of transpharyngeal Doppler to assess cerebral perfusion during cardiovascular surgery
Study NCT03494413 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Conventional colour-coded Duplex sonography (CDS)
Description: Usage of conventional colour-coded Duplex sonography (CDS) to assess cerebral perfusion during cardiovascular surgery